Nuclear phospholipase C-β1 and diacylglycerol LIPASE-α in brain cortical neurons.
Phosphoinositide (PtdIns) signaling involves the generation of lipid second messengers in response to stimuli in a receptor-mediated manner at the plasma membrane. In neuronal cells of adult brain, the standard model proposes that activation of metabotropic receptors coupled to Phospholipase C-β1 (PLC-β1) is linked to endocannabinoid signaling through the production of diacylglycerol (DAG), which could be systematically metabolized by 1,2-diacylglycerol Lipases (DAGL) to produce an increase of 2-arachidonoyl-glycerol (2-AG), the most abundant endocannabinoid in the brain. However, the existence of a nuclear PtdIns metabolism independent from that occurring elsewhere in the cell is now widely accepted, suggesting that the nucleus constitutes both a functional and a distinct compartment for PtdIns metabolism. In this review, we shall highlight the main achievements in the field of neuronal nuclear inositol lipid metabolism with particular attention to progress made linked to the 2-AG biosynthesis. Our aim has been to identify potential sites of 2-AG synthesis other than the neuronal cytoplasmic compartment by determining the subcellular localization of PLC-β1 and DAGL-α, which is much more abundant than DAGL-β in brain. Our data show that PLC-β1 and DAGL-α are detected in discrete brain regions, with a marked predominance of pyramidal morphologies of positive cortical cells, consistent with their role in the biosynthesis and release of 2-AG by pyramidal neurons to control their synaptic inputs. However, as novelty, we showed here an integrated description of the localization of PLC-β1 and DAGL-α in the neuronal nuclear compartment. We discuss our comparative analysis of the expression patterns of PLC-β1 and DAGL-α, providing some insight into the potential autocrine role of 2-AG production in the neuronal nuclear compartment that probably subserve additional roles to the recognized activation of the CB1 cannabinoid receptor.
Departamento de Neurociencias, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain.
Gontzal
G
García del Caño
Departamento de Farmacología, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain; CIBERSAM, Spain.
Mario
M
Montaña
Departamento de Neurociencias, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain.
Xabier
X
Aretxabala
Departamento de Farmacología, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain.
Imanol
I
González-Burguera
Departamento de Farmacología, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain; CIBERSAM, Spain.
Maider
M
López de Jesús
Departamento de Farmacología, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain; CIBERSAM, Spain.
Sergio
S
Barrondo
Departamento de Farmacología, Facultad de Farmacia (Vitoria-Gasteiz), Universidad del País Vasco (UPV/EHU), Spain; CIBERSAM, Spain. Electronic address: joan.salles@ehu.es.
Joan
J
Sallés
D000818:Animals; D001921:Brain / Q000166:cytology / Q000201:enzymology; D002467:Cell Nucleus / Q000201:enzymology* / Q000235:genetics; D002540:Cerebral Cortex / Q000166:cytology / Q000201:enzymology*; D004075:Diglycerides / Q000378:metabolism; D006801:Humans; D008071:Lipoprotein Lipase / Q000235:genetics / Q000378:metabolism*; D009474:Neurons / Q000201:enzymology*; D054799:Phospholipase C beta / Q000235:genetics / Q000378:metabolism*
C011439:1,2-diacylglycerol; D004075:Diglycerides; D008071:Lipoprotein Lipase; D054799:Phospholipase C beta